Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development.
Our ability to turn great products into great medicines has never been more reliant on how we engage with our patients, yet we’re still falling short of expectations and failing to build su
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
